The FDA has approved Phesgo™ (pertuzumab, trastuzumab, hyaluronidase-zzxf; Genentech), in combination with chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer.
The detection of acquired ESR1 mutations in patients with hormone receptor (HR) positive metastatic breast cancer predicted poor clinical benefit from exemestane.
The TC model uses various parameters to predict risk such as genetic risk and nonfamilial factors including personal, hormonal, and lifestyle characteristics.
Controversy exists regarding whether to offer early locoregional treatment in addition to palliative therapy to patients with de novo MBC and an intact primary tumor.
Nearly half of the patients with advanced HER2-positive breast cancer enrolled in the randomized, phase II HER2CLIMB trial had disease that had metastasized to the brain.
PI3KCA is mutated in approximately 40% of patients with HR-positive, HER2-negative advanced breast cancer, and is associated with treatment resistance and poor outcomes.
Researchers found that PET responders exhibited least a 40% reduction in SUVmax of 18F-FDG PET/CT compared with baseline following initial neoadjuvant therapy.
Researchers sought to compare neoadjuvant chemotherapy with an epirubicin-based regimen to a non-anthracycline-containing regimen in HER2-positive breast cancer.
Margin size was not associated with locoregional recurrence for patients with breast cancer who underwent breast-conserving surgery and neoadjuvant chemotherapy.
A review of prior screening mammograms of patients diagnosed with breast cancer allowed for the retrospective identification of previously missed tumors.
